The sector at a glance

The figures below are drawn from Algerian government statements and industry press through late 2025. Where official sources differ, we show the range rather than a single number.

Note: plant counts vary by source and definition, official statements cite figures from ~203 to ~233 pharmaceutical establishments depending on date and scope.

Reading the numbers as a talent story

Each of these figures is, underneath, a workforce figure. A jump from $3.14B to over $4B in production in two years does not happen without people to run the lines, release the batches and file the dossiers. More than 780 production lines require qualified operators, maintenance engineers and QC analysts. Producing 3,400+ molecules, including increasingly complex ones, demands regulatory and quality expertise at scale.

The most telling indicator is the pipeline: 103 investment projects under study, with 72 in medicines. Each new unit that comes online will need a full technical team before it can release a single batch. In other words, the demand curve for specialized talent is set to steepen well before the supply of experienced professionals can catch up.

The missing metric: sector employment

Here is the honest limit of any Algerian pharma HR barometer today: there is no single, regularly published, consolidated figure for total employment across the pharmaceutical industry. Official communication is rich on plants, coverage rates and production value, and comparatively silent on headcount, role mix, vacancy rates or time-to-fill.

That gap is itself a finding. For a sector positioned as strategic to health sovereignty, the absence of standardized human-capital data makes workforce planning harder for everyone, public authorities, employers and universities alike. Any headcount figure circulating without a clear, dated official source should be treated with caution rather than repeated as fact.

Where the hiring pressure concentrates

Reading the industry’s own priorities, local raw-material production launching from 2025, biosimilars manufacturing on the agenda of the 9th National Pharmacy Congress (December 2025), and a wave of new units, points to where demand is most acute:

• Quality assurance & regulatory affairs, the compliance backbone of every new line
• Process & industrial pharmacists, validation, scale-up and GMP operations
• Maintenance & automation engineers, to keep 780+ lines running
• Bioproduction specialists, as biosimilars and complex products expand
• Analytical chemists for QC laboratories and raw-material control

À retenir

Algeria’s pharmaceutical numbers tell a clear human-capital story: production, coverage and investment are climbing fast, and every point of growth deepens the need for specialized talent. Yet the industry lacks consolidated employment data, the very metric HR strategy depends on. Employers who track their own workforce indicators, invest early in training, and source through specialized channels will navigate the tightening market far better than those flying blind.

Sources & methodology

Figures reflect Algerian government statements and industry press through late 2025. Ranges are shown where official sources differ. No consolidated official sector-employment figure was available at the time of writing.

• Maghreb Pharma Expo, “With 218 plants, Algeria accounts for 30% of Africa’s pharmaceutical industry” (May 2025)
• APS / Algérie Éco, pharmaceutical production expected to exceed $4 billion in 2024
• DzairTube / ElDjazair Today, over 80% of national demand met by local production (2025)
• Radio Algérienne, evolution of the sector and national production units
• Maghreb Info, 103 new investment projects (72 medicines, 31 medical devices), late 2025
• L’Algérie Aujourd’hui, medicine imports down from $1.25B (2022) to $515M (2024)
• Fédération Algérienne de Pharmacie, 9th National Congress (18-20 Dec 2025), biosimilars manufacturing on the agenda